Seres Therapeutics (NASDAQ:MCRB) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday.
According to Zacks, “Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “
Separately, BidaskClub cut Seres Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, March 9th. Three investment analysts have rated the stock with a sell rating and eight have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $18.29.
Shares of MCRB stock opened at $8.32 on Friday. The company has a market capitalization of $332.54 million, a price-to-earnings ratio of -3.76 and a beta of 0.49. The company has a quick ratio of 4.90, a current ratio of 4.90 and a debt-to-equity ratio of 0.15. Seres Therapeutics has a fifty-two week low of $8.07 and a fifty-two week high of $8.38.
Seres Therapeutics (NASDAQ:MCRB) last issued its earnings results on Wednesday, May 9th. The biotechnology company reported ($0.69) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.75) by $0.06. The business had revenue of $3.97 million during the quarter, compared to the consensus estimate of $3.00 million. Seres Therapeutics had a negative return on equity of 117.66% and a negative net margin of 277.79%. research analysts anticipate that Seres Therapeutics will post -2.65 earnings per share for the current year.
In related news, insider John G. Aunins sold 14,279 shares of Seres Therapeutics stock in a transaction that occurred on Wednesday, April 25th. The stock was sold at an average price of $7.58, for a total transaction of $108,234.82. Following the transaction, the insider now owns 184,485 shares of the company’s stock, valued at $1,398,396.30. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 41.90% of the company’s stock.
Large investors have recently made changes to their positions in the stock. Cubist Systematic Strategies LLC purchased a new position in shares of Seres Therapeutics during the third quarter valued at approximately $170,000. Arrowstreet Capital Limited Partnership purchased a new position in shares of Seres Therapeutics during the fourth quarter valued at approximately $143,000. Wells Fargo & Company MN boosted its position in shares of Seres Therapeutics by 107.2% during the fourth quarter. Wells Fargo & Company MN now owns 29,183 shares of the biotechnology company’s stock valued at $296,000 after buying an additional 15,097 shares during the last quarter. Lakeview Capital Partners LLC purchased a new position in shares of Seres Therapeutics during the fourth quarter valued at approximately $346,000. Finally, Virtus Fund Advisers LLC purchased a new position in shares of Seres Therapeutics during the fourth quarter valued at approximately $358,000. 78.98% of the stock is currently owned by institutional investors.
Seres Therapeutics Company Profile
Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. Its lead product candidate is SER-109, a bacterial spore ecology, which is in Phase III clinical study to treat multiply recurrent Clostridium difficile infection (CDI).
Get a free copy of the Zacks research report on Seres Therapeutics (MCRB)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.